uniQure stock heads into quarterly results with webcast scheduled
Published on 11/03/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch next
- uniQure plans to publish third-quarter 2026 results before the US market opens on Wednesday, November 4.
- Management will discuss the figures in an 8:30 a.m. ET conference call and webcast.
- The company is advancing gene therapies for Huntington's disease, epilepsy, Fabry disease and other severe conditions.
uniQure is due to release its third-quarter 2026 financial results before the US market opens on Wednesday, November 4. The company announced the timing on October 28, and BioSpace carried the release from GlobeNewswire.
Management plans to host a conference call at 8:30 a.m. ET after the results are published. Investors can follow the event through the company's Events & Presentations section, while a replay is scheduled to remain available for 90 days.
Results set the next catalyst
The report will give investors a fresh view of uniQure's financial position and development pipeline. The company is working on gene therapies for Huntington's disease, refractory temporal lobe epilepsy, Fabry disease and other severe conditions, according to the company description included with the announcement.
BioSpace reported that analysts seeking to participate in the question-and-answer session can join by phone using conference ID 5075555.
uniQure stock traded at 20.37 euros on Lang & Schwarz at 13:33 CET on Tuesday, November 3, 2026.
Investors can follow the real-time quote of uniQure stock during the session.
US biotech shares will trade against the wider backdrop of the Nasdaq Composite.
More news and analyses on uniQure stock are available in the topic overview.
uniQure stock at a glance
- Company: uniQure N.V.
- ISIN: NL0010696654
- Ticker: QURE
- Exchange: Lang & Schwarz
- Price: 20.37 euros on November 3, 2026 at 13:33 CET
